Bayer Toekomstige groei
Future criteriumcontroles 3/6
Bayer zal naar verwachting groeien in winst en omzet met respectievelijk 44.3% en 2.6% per jaar. De winst per aandeel zal naar verwachting groeien met 47.4% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 15.8% zijn.
Belangrijke informatie
44.3%
Groei van de winst
47.40%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 23.7% |
| Inkomstengroei | 2.6% |
| Toekomstig rendement op eigen vermogen | 15.79% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 18 May 2026 |
Recente toekomstige groei-updates
Recent updates
Narratiefupdate • May 22
BAYN: Easing Litigation Risks Will Support Re Rating And Future Upside Potential
Analysts have maintained the fair value estimate for Bayer at €60.00 and raised price targets in recent research, citing a series of upgrades, slightly higher assumptions for revenue growth and profit margins, as well as a modestly lower future P/E multiple following a broad reassessment of sector risks and company-specific legal developments. Analyst Commentary Recent research points to a clear shift toward more constructive views on Bayer, with several bullish analysts updating ratings and valuation frameworks in response to company specific developments and sector wide reassessments.
Narratiefupdate • May 05
BAYN: Future Litigation And Settlement Uncertainty Will Constrain Share Upside Potential
Analysts have nudged the fair value estimate for Bayer higher to about €31.26 from €30.41, citing a series of recent upgrades and higher price targets that reflect updated assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on Bayer has been mixed, with several firms updating ratings and price targets over the past few months.Narratiefupdate • Apr 21
BAYN: Future Litigation Settlement Payouts Will Pressure Upside Potential
Analysts have lifted the Bayer fair value estimate from €23.00 to about €30.41, citing a series of recent price target increases and upgrades that reflect updated assumptions for revenue growth, profit margins, and P/E expectations. Analyst Commentary Recent research on Bayer shows a split in sentiment, with some firms becoming more constructive while others highlight ongoing risks to the investment case.Narratiefupdate • Apr 06
BAYN: Roundup Settlement Progress Will Reduce Litigation Overhang And Support Future Upside
Analysts maintain a fair value estimate for Bayer at €60.00. Recent adjustments to revenue growth, margin, and P/E assumptions come alongside mixed research actions, including several upgrades that point to potential resolution of litigation overhangs and margin upside, offset by at least one downgrade with a lower price target.Narratiefupdate • Mar 23
BAYN: Roundup Settlement Advances Will Support Future Upside In Core Earnings
Analysts have modestly adjusted Bayer's price targets to a range of €50 to €55, reflecting mixed views that balance recent upgrades tied to share price weakness, litigation progress and margin potential with at least one more cautious stance. Analyst Commentary Recent research points to a cluster of more optimistic views on Bayer, with several bullish analysts raising ratings or price targets as they reassess litigation risk, product potential and profitability in key segments.Narratiefupdate • Mar 09
BAYN: Roundup Settlement Progress Will Support Future Upside In Core Earnings
Analysts have revised their view on Bayer with a reduced implied P/E and updated margin expectations, while recent Street research shows a split between a Sell call at €42 and an Overweight stance at €45 that hinges on litigation resolution and potential upside in pharmaceuticals and Crop Science. Analyst Commentary Recent research on Bayer highlights a clear divide between cautious and optimistic views, with valuation closely linked to how investors think litigation, pharmaceutical assets and Crop Science margins will play out.Narratiefupdate • Feb 23
BAYN: Roundup Settlement Progress Will Unlock Future Equity Upside
The analyst fair value estimate for Bayer has been adjusted to €60 from €55. This reflects updated assumptions on revenue growth and future P/E, alongside mixed Street views, including a downgrade citing valuation risks and an upgrade pointing to potential progress on litigation and margins.Narratiefupdate • Feb 09
BAYN: Litigation Overhang Resolution Will Unlock Future Equity Upside
Analysts have nudged their Bayer price targets higher, with recent moves such as Barclays shifting to an Overweight rating with a €45 target and Berenberg raising its target to €30.40. They cite potential resolution of litigation issues, along with possible upside in Kerendia and Crop Science margins, as key supports for their updated views.Analyseartikel • Jan 27
The Market Lifts Bayer Aktiengesellschaft (ETR:BAYN) Shares 29% But It Can Do More
Despite an already strong run, Bayer Aktiengesellschaft ( ETR:BAYN ) shares have been powering on, with a gain of 29...Narratiefupdate • Jan 25
BAYN: Litigation Resolution And Crop Science Margins Will Unlock Future Upside
Analysts have raised their fair value estimate for Bayer from €47.98 to €55.00, citing the potential resolution of litigation issues, improved expectations for Kerendia, and margin opportunities in the Crop Science business as key supports for the higher target. Analyst Commentary Recent Street research points to a more constructive tone around Bayer, with several bullish analysts adjusting their views in ways that support the higher fair value estimate.
Narratiefupdate • Jan 09
BAYN: Litigation Overhang Will Drive Future Rerating Risk For Shares
Narrative Update Analysts have nudged their fair value estimate for Bayer from €33.42 to €34.97, citing updated assumptions for modestly higher revenue growth, slightly stronger profit margins, a higher future P/E, and growing confidence that litigation issues, Kerendia expectations, and Crop Science margins could be better than previously modeled. Analyst Commentary Recent Street research on Bayer has focused on how quickly the litigation overhang could be addressed, the role of Kerendia in the pharma portfolio, and the strength of margins in Crop Science.Narratiefupdate • Dec 26
BAYN Will Rely On Pipeline And Cost Cuts To Unlock Upside Potential
Analysts have raised their price target on Bayer to approximately EUR 48 from around EUR 37. They cite expectations for slightly faster revenue growth, improved profit margins, a modestly lower discount rate and a higher future earnings multiple that together support a higher fair value.Narratiefupdate • Dec 11
BAYN: Future Litigation Outcomes And Potential Ag Spin-Out Will Shape Shares
Analysts have nudged their Bayer price target higher to about EUR 30 from the mid‑20s, citing slightly faster expected revenue growth, modestly stronger profit margins, and a richer future P/E multiple. Together, these factors lift estimated fair value to roughly EUR 33 per share.Analyseartikel • Dec 03
Further Upside For Bayer Aktiengesellschaft (ETR:BAYN) Shares Could Introduce Price Risks After 27% Bounce
Bayer Aktiengesellschaft ( ETR:BAYN ) shareholders have had their patience rewarded with a 27% share price jump in the...Narratiefupdate • Nov 27
BAYN: Future Litigation Decisions And Agriculture Spin-Out Will Guide Shares
Bayer's analyst price target increased from EUR 28.71 to EUR 29.57, as analysts cite improved forecasts for revenue growth and a recent uptick in target valuations across the sector. Analyst Commentary Bullish Takeaways Bullish analysts have raised Bayer's price targets in response to improved revenue forecasts.Analyseartikel • Nov 14
Bayer Aktiengesellschaft (ETR:BAYN) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
It's been a pretty great week for Bayer Aktiengesellschaft ( ETR:BAYN ) shareholders, with its shares surging 13% to...Narratiefupdate • Nov 13
BAYN: Future Legal Outcomes And Sector Dynamics Will Determine Momentum
Analysts have raised Bayer's price target slightly from $28.53 to $28.71, reflecting steady profit margin improvements and updated industry positioning. This adjustment comes particularly in light of ongoing strategic shifts among major agribusiness peers.Analyseartikel • Jul 13
Is Bayer (ETR:BAYN) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Nieuw narratief • Nov 24
Innovative Launches And Decisive Moves Set Stage For Remarkable Growth In Pharmaceuticals And Consumer Health
Pharmaceutical and agriculture innovations are key strategies for growth, offsetting generic competition and boosting future revenues.Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2028 | 48,422 | 3,607 | 4,449 | 7,816 | 14 |
| 12/31/2027 | 46,768 | 3,045 | 3,855 | 7,389 | 18 |
| 12/31/2026 | 45,516 | 2,161 | -1,658 | 1,715 | 17 |
| 3/31/2026 | 45,242 | -2,156 | 2,641 | 5,151 | N/A |
| 12/31/2025 | 45,575 | -3,620 | 3,443 | 5,930 | N/A |
| 9/30/2025 | 45,866 | -198 | 3,937 | 6,725 | N/A |
| 6/30/2025 | 46,174 | -3,418 | 4,594 | 7,151 | N/A |
| 3/31/2025 | 46,579 | -3,253 | 5,783 | 8,503 | N/A |
| 12/31/2024 | 46,606 | -2,552 | 4,590 | 7,368 | N/A |
| 9/30/2024 | 46,739 | -880 | 5,303 | 7,978 | N/A |
| 6/30/2024 | 47,113 | -1,266 | 5,690 | 8,443 | N/A |
| 3/31/2024 | 47,013 | -3,119 | 3,786 | 6,517 | N/A |
| 12/31/2023 | 47,637 | -2,941 | 2,366 | 5,117 | N/A |
| 9/30/2023 | 47,775 | -3,667 | -508 | 2,571 | N/A |
| 6/30/2023 | 48,714 | 1,448 | -473 | 2,649 | N/A |
| 3/31/2023 | 50,489 | 3,037 | 1,203 | 4,269 | N/A |
| 12/31/2022 | 50,739 | 4,150 | 4,144 | 7,093 | N/A |
| 9/30/2022 | 49,857 | 4,700 | 4,313 | 7,078 | N/A |
| 6/30/2022 | 48,357 | 4,239 | 4,547 | 7,235 | N/A |
| 3/31/2022 | 46,392 | 2,202 | 4,497 | 7,128 | N/A |
| 12/31/2021 | 44,081 | 1,000 | 2,478 | 5,089 | N/A |
| 9/30/2021 | 42,958 | 222 | 430 | 2,794 | N/A |
| 6/30/2021 | 41,683 | -7,565 | -314 | 1,950 | N/A |
| 3/31/2021 | 40,883 | -14,849 | 11 | 2,367 | N/A |
| 12/31/2020 | 41,400 | -15,569 | 2,485 | 4,903 | N/A |
| 9/30/2020 | 42,155 | -15,995 | 4,805 | 7,398 | N/A |
| 6/30/2020 | 43,479 | -7,303 | 4,940 | 7,713 | N/A |
| 3/31/2020 | 44,138 | 2,631 | 4,253 | 6,899 | N/A |
| 12/31/2019 | 43,545 | 2,391 | N/A | 8,207 | N/A |
| 9/30/2019 | 43,150 | -1,530 | N/A | 7,929 | N/A |
| 6/30/2019 | 42,581 | 287 | N/A | 7,698 | N/A |
| 3/31/2019 | 39,856 | 557 | N/A | 8,338 | N/A |
| 12/31/2018 | 36,742 | 1,374 | N/A | 7,917 | N/A |
| 9/30/2018 | 34,983 | 6,027 | N/A | 7,218 | N/A |
| 6/30/2018 | 33,747 | 3,237 | N/A | 7,878 | N/A |
| 3/31/2018 | 34,473 | 3,486 | N/A | 7,951 | N/A |
| 12/31/2017 | 35,015 | 3,249 | N/A | 8,134 | N/A |
| 9/30/2017 | 35,242 | 3,087 | N/A | 8,597 | N/A |
| 6/30/2017 | 35,475 | 3,924 | N/A | 8,939 | N/A |
| 3/31/2017 | 32,769 | 3,991 | N/A | 8,608 | N/A |
| 12/31/2016 | 34,943 | 3,743 | N/A | 9,089 | N/A |
| 9/30/2016 | 37,405 | 3,837 | N/A | 8,234 | N/A |
| 6/30/2016 | 40,151 | 3,971 | N/A | 7,511 | N/A |
| 3/31/2016 | 46,146 | 4,210 | N/A | 7,488 | N/A |
| 12/31/2015 | 46,085 | 4,025 | N/A | 6,890 | N/A |
| 9/30/2015 | 45,592 | 3,616 | N/A | 7,243 | N/A |
| 6/30/2015 | 44,555 | 3,429 | N/A | 6,729 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: Er wordt voorspeld dat BAYN de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 1.9% ).
Winst versus markt: Er wordt verwacht dat BAYN de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.
Hoge groeiwinsten: Er wordt verwacht dat BAYN binnen 3 jaar winstgevend zal worden.
Omzet versus markt: De omzet van BAYN ( 2.6% per jaar) zal naar verwachting langzamer groeien dan de markt German ( 6.8% per jaar).
Hoge groei-inkomsten: De omzet van BAYN ( 2.6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen BAYN zal naar verwachting over 3 jaar laag zijn ( 15.8 %).
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/24 10:16 |
| Aandelenkoers aan het einde van de dag | 2026/05/22 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Bayer Aktiengesellschaft wordt gevolgd door 42 analisten. 18 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Rafael Bonardell Trianes | Banco de Sabadell. S.A. |
| Emily Field | Barclays |
| Charles Pitman | Barclays |